as 08-29-2025 1:31pm EST
Journey Medical Corp is a commercial stage pharmaceutical company focused on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions. The company's current product portfolio includes eight FDA-approved prescription drugs for dermatological conditions that are marketed in the U.S. Some of the group's products are Qbrexza, Accutane, Amzeeq, Exelderm and others.
Founded: | 2014 | Country: | United States |
Employees: | N/A | City: | SCOTTSDALE |
Market Cap: | 165.6M | IPO Year: | 2021 |
Target Price: | $12.67 | AVG Volume (30 days): | 198.2K |
Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -0.40 | EPS Growth: | N/A |
52 Week Low/High: | $3.54 - $8.90 | Next Earning Date: | 08-12-2025 |
Revenue: | $56,397,000 | Revenue Growth: | -27.40% |
Revenue Growth (this year): | 28.1% | Revenue Growth (next year): | 53.84% |
DERM Breaking Stock News: Dive into DERM Ticker-Specific Updates for Smart Investing
MT Newswires
2 months ago
GlobeNewswire
2 months ago
MT Newswires
2 months ago
GlobeNewswire
2 months ago
TipRanks
2 months ago
GlobeNewswire
2 months ago
GlobeNewswire
3 months ago
Yahoo Finance Video
3 months ago
The information presented on this page, "DERM Journey Medical Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.